Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia
- 1 April 2001
- journal article
- clinical trial
- Published by Elsevier in Schizophrenia Research
- Vol. 49 (3) , 243-251
- https://doi.org/10.1016/s0920-9964(00)00083-9
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- α‐Linolenic Acid Dietary Deficiency Alters Age‐Related Changes of Dopaminergic and Serotoninergic Neurotransmission in the Rat Frontal CortexJournal of Neurochemistry, 1996
- Increased platelet phospholipase A2 activity in schizophreniaSchizophrenia Research, 1995
- The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Red blood cell membrane dynamics in schizophrenia. II. Fatty acid compositionSchizophrenia Research, 1994
- Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy studySchizophrenia Research, 1994
- Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measuresSchizophrenia Research, 1994
- Eicosapentaenoic Acid Enhances Intracellular Free Calcium in Cultured Human EndothelialCellsBiochemical Medicine and Metabolic Biology, 1994
- Phospholipase A2 Activity in Serum of Neuroleptic-Naive Psychiatric InpatientsPharmacopsychiatry, 1993
- Schizophrenia and rheumatoid arthritis: a reviewSchizophrenia Research, 1992
- The Role of Membrane Lipids in Receptor MechanismsAnnual Review of Pharmacology and Toxicology, 1980